Apyx Medical Publishes New Renuvion Clinical Data

What Happened Apyx Medical Corporation (APYX) filed an 8-K on September 29, 2026 (Item 8.01) to announce the publication of new clinical data in the journal Plastic and Reconstructive Surgery—Global Open. The published results come from a prospective clinical study evaluating the effects of the company’s Renuvion helium plasma radiofrequency technology on biological markers of skin quality. A company press release announcing the publication was attached to the filing as Exhibit 99.1.

Key Details

• Filing date: September 29, 2026 (Form 8-K, Item 8.01).
• Publication: Results published in Plastic and Reconstructive Surgery—Global Open.
• Study type: Prospective clinical study assessing biological markers of skin quality.
• Disclosure: Company press release announcing the publication is attached as Exhibit 99.1 to the 8-K.

Why It Matters Publication of clinical data in a peer-reviewed journal provides independent visibility and scientific documentation of Renuvion’s effects on skin-quality biomarkers. For investors, peer-reviewed results can support the device’s clinical credibility, aid in marketing and clinician adoption discussions, and inform assessments of Apyx’s product pipeline and commercial potential. The 8-K itself is a formal notification of the publication and links to the company’s press release for full details.